CME/CE
Jointly provided by Partners for Advancing Clinical Education (Partners) and DKBmed, LLC.
Acknowledgement
This activity is supported by educational grants from Genetech and Regeneron Pharmaceuticals Inc.
Target Audience
The target audience includes retina specialists as well as comprehensive ophthalmologists.
Educational Objectives
Upon completion of this activity, participants should be able to:
- Discuss effects of delayed and interrupted treatment for DME.
- Evaluate the benefits of newly available anti-VEGF treatment options for DR and DME that may improve visual outcomes.
Disclosures
Partners requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.
Faculty / Presenter Reported Financial Relationship
| Faculty | Conflicts of Interest |
| Grayson W. Armstrong, MD, MPH | Consultant, Advisor, Speaker: Ocular Technologies Inc, McKinsey & Company, Dynamed, Optomed, Xenon Ophthalmics, Kriya Therapeutics |
| John W. Kitchens, MD | Consultant, Advisor, Speaker: Alcon, Apellis, Astellas, Bayer, Genentech/Roche, Regeneron
Advisor, Consultant: Outlook, Zeiss, Harrow, Eyepoint Pharmaceuticals, Neurotech, ANI, Ocular Therapeutix, Cencora, Amgen Consultant: Abbvie |
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and DKBmed LLC. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Education
Partners designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hours.
PA Continuing Medical Education
Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until 10/28/26. PAs should only claim credit commensurate with the extent of their participation.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
There are no fees for participating and receiving CME/CE credit for this activity.
Request for Credit
If you wish to receive acknowledgment for completing this activity, please complete the evaluation.
- Release date: 10/28/25
- Expiration date: 10/28/26
Estimated time to complete the activity: 60 minutes
Hardware & Software Requirements
To access activities, users will need:
- A computer with an internet connection
- An HTML5 compliant web browser or Internet Explorer 8 (and higher)
Contact Information
For additional information about the accreditation of this activity, please visit https://partnersed.com
CME/CE
Jointly provided by Partners for Advancing Clinical Education (Partners) and DKBmed, LLC.
Acknowledgement
This activity is supported by educational grants from Genetech and Regeneron Pharmaceuticals Inc.
Target Audience
The target audience includes retina specialists as well as comprehensive ophthalmologists.
Educational Objectives
Upon completion of this activity, participants should be able to:
- Discuss consequences of delayed or interrupted treatment for nAMD.
- Describe efficacy and safety of newer anti-VEGF treatments for nAMD.
Disclosures
Partners requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.
Faculty / Presenter Reported Financial Relationship
| Faculty | Conflicts of Interest |
| Joseph M. Coney, MD, FACS, FASRS | Researcher: 4DMT, AbbVie/Allergan, Alimera Sciences, ANI Pharmaceuticals, Aviceda Therapeutics, Eyebiotech Limited, MacTel, Neurotech, National Eye Institute, REGENXBIO
Consultant, Advisor, Speaker: 4DMT, AbbVie/Allergan, Alimera Sciences, ANI Pharmaceuticals, Astellas/IvericBio, Bausch & Lomb Americas Researcher, Consultant, Advisor, Speaker: Apellis, Genentech/Roche, Regeneron Consultant: Coherus Biosciences |
| John W. Kitchens, MD | Consultant, Advisor, Speaker: Alcon, Apellis, Astellas, Bayer, Genentech/Roche, Regeneron
Advisor, Consultant: Outlook, Zeiss, Harrow, Eyepoint Pharmaceuticals, Neurotech, ANI, Ocular Therapeutix, Cencora, Amgen Consultant: Abbvie |
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and DKBmed LLC. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Education
Partners designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hours.
PA Continuing Medical Education
Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until 11/25/26. PAs should only claim credit commensurate with the extent of their participation.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
There are no fees for participating and receiving CME/CE credit for this activity.
Request for Credit
If you wish to receive acknowledgment for completing this activity, please complete the evaluation.
- Release date: 11/25/25
- Expiration date: 11/25/26
Estimated time to complete the activity: 60 minutes
Hardware & Software Requirements
To access activities, users will need:
- A computer with an internet connection
- An HTML5 compliant web browser or Internet Explorer 8 (and higher)
Contact Information
For additional information about the accreditation of this activity, please visit https://partnersed.com
CME/CE
Jointly provided by Partners for Advancing Clinical Education (Partners) and DKBmed, LLC.
Acknowledgement
This activity is supported by educational grants from Genetech and Regeneron Pharmaceuticals Inc.
Target Audience
The target audience includes retina specialists as well as comprehensive ophthalmologists.
Educational Objectives
Upon completion of this activity, participants should be able to:
- Describe prevalence of interrupted care for RVO.
- Assess the efficacy of newer treatments for RVO.
Disclosures
Partners requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.
Faculty / Presenter Reported Financial Relationship
| Faculty | Conflicts of Interest |
| Grayson W. Armstrong, MD, MPH | Consultant, Advisor, Speaker: Ocular Technologies Inc, McKinsey & Company, Dynamed, Optomed, Xenon Ophthalmics, Kriya Therapeutics |
| Joseph M. Coney, MD, FACS, FASRS | Researcher: 4DMT, AbbVie/Allergan, Alimera Sciences, ANI Pharmaceuticals, Aviceda Therapeutics, Eyebiotech Limited, MacTel, Neurotech, National Eye Institute, REGENXBIO
Consultant, Advisor, Speaker: 4DMT, AbbVie/Allergan, Alimera Sciences, ANI Pharmaceuticals, Astellas/IvericBio, Bausch & Lomb Americas Researcher, Consultant, Advisor, Speaker: Apellis, Genentech/Roche, Regeneron Consultant: Coherus Biosciences |
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and DKBmed LLC. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Education
Partners designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hours.
PA Continuing Medical Education
Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until 12/16/26. PAs should only claim credit commensurate with the extent of their participation.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
There are no fees for participating and receiving CME/CE credit for this activity.
Request for Credit
If you wish to receive acknowledgment for completing this activity, please complete the evaluation.
- Release date: 12/16/25
- Expiration date: 12/16/26
Estimated time to complete the activity: 60 minutes
Hardware & Software Requirements
To access activities, users will need:
- A computer with an internet connection
- An HTML5 compliant web browser or Internet Explorer 8 (and higher)
Contact Information
For additional information about the accreditation of this activity, please visit https://partnersed.com